RUNX1 translocations and fusion genes in malignant hemopathies

Future Oncology

Volumn 7, Issue 1, 2011, Pages 77-91

  De Braekeleer, Etienne ^a,b,c   Douet Guilbert, Nathalie ^a,b,c   Morel, Frédéric ^a,b,c   Le Bris, Marie Josée ^c   Férec, Claude ^a,c   De Braekeleer, Marc ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c CHRU Brest   (France)

Author keywords

acute leukemia; fusion gene; gene transcription; myelodysplastic syndrome; RUNX1; translocation

Indexed keywords

HYBRID PROTEIN; NUCLEIC ACID BINDING PROTEIN; ONCOPROTEIN; PEROXIREDOXIN 4; PROTEIN AFF3; PROTEIN AMP19; PROTEIN CBFA2T3; PROTEIN CPNE8; PROTEIN FGA7; PROTEIN LPXN; PROTEIN MACROD1; PROTEIN MECOM; PROTEIN RPL22L1; PROTEIN SH3D19; PROTEIN TRPS1; PROTEIN USP16; PROTEIN USP42; PROTEIN YTHDF2; PROTEIN ZFPM2; PROTEIN ZNF687; TRANSCRIPTION FACTOR ETV6; TRANSCRIPTION FACTOR PRDM16; TRANSCRIPTION FACTOR RUNX; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR RUNX1T1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 21Q; CHROMOSOME BAND; CHROMOSOME REARRANGEMENT; CHROMOSOME TRANSLOCATION; CHROMOSOME TRANSLOCATION 20; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 3; CHRONIC MYELOID LEUKEMIA; FUSION GENE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE REARRANGEMENT; GENE REPRESSION; GENE SEQUENCE; GENE STRUCTURE; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPE; LEUKEMIA; PRIORITY JOURNAL;

CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE FUSION; GENE REARRANGEMENT; GENETIC ASSOCIATION STUDIES; HEMATOLOGIC NEOPLASMS; HUMANS; TRANSLOCATION, GENETIC;

EID: 78650614382     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.158     Document Type: Article

References (147)

1. Okuda T, van Deursen J, Hiebert SW et al.: AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84, 321-330 (1996).
2. Ito Y: Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 23, 4198-4208 (2004).
3. Okuda T, Cai Z, Yang S et al.: Expression of knocked-in AML1-ETO leukemia gene inhibits the establishment of normal defnitive hematopoiesis and directly generates dysplastic hematopoietic progenitors. Blood 91, 3134-3143 (1998).
4. North TE, de Bruijn MF, Stacy T et al.: Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. Immunity 16, 661-672 (2002).
5. Levanon D, Groner Y: Structure and regulated expression of mammalian RUNX genes. Oncogene 23, 4211-4219 (2004).
6. de Bruijn MF, Speck NA: Core-binding factors in hematopoiesis and immune function. Oncogene 23, 4238-4248 (2004).
7. Ito Y: RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 99, 33-76 (2008).
8. Kagoshima H, Shigesada K, Satake M et al.: The Runt domain identifes a new family of heteromeric transcriptional regulators. Trends Genet. 9, 338-341 (1993).
9. Tanaka T, Kurokawa M, Ueki K et al.: The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol. Cell Biol. 16, 3967-3979 (1996).
10. Kanno T, Kanno Y, Chen LF et al.: Intrinsic transcriptional activation-inhibition domains of the polyomavirus enhancer binding protein 2/core binding factor α subunit revealed in the presence of the β subunit. Mol. Cell Biol. 18, 2444-2454 (1998).
11. Zeng C, van Wijnen AJ, Stein JL et al.: Identifcation of a nuclear matrix targeting signal in the leukemia and bone-related AML/CBF-α transcription factors. Proc. Natl Acad. Sci. USA 94, 6746-6751 (1997). Yamaguchi Y, Kurokawa M, Imai Y et al.: AML1 is functionally regulated through p300-mediated acetylation on specifc lysine residues. J. Biol. Chem. 279, 15630-15638 (2004).
12. Levanon D, Glusman G, Bangsow T et al.: Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1. Gene 262, 23-33 (2001).
13. Osato M: Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23, 4284-4296 (2004).
14. Levanon D, Bernstein Y, Negreanu V et al.: A large variety of alternatively spliced and differentially expressed mRNAs are encoded by the human acute myeloid leukemia gene AML1. DNA Cell. Biol. 15, 175-185 (1996).
15. Ito Y: Molecular basis of tissue-specifc gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells 4, 685-696 (1999).
16. Tanaka T, Tanaka K, Ogawa S et al.: An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. EMBO J. 14, 341-350 (1995).
17. Michaud J, Scott HS, Escher R: AML1 interconnected pathways of leukemogenesis. Cancer Invest. 21, 105-136 (2003).
18. De Braekeleer E, Ferec C, De Braekeleer M: RUNX1 translocations in malignant hemopathies. Anticancer Res. 29, 1031-1038 (2009).
19. Kurokawa M, Hirai H: Role of AML1/Runx1 in the pathogenesis of hematological malignancies. Cancer Sci. 94, 841-846 (2003).
20. Imai Y, Kurokawa M, Tanaka K et al.: TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem. Biophys. Res. Commun. 252, 582-589 (1998).
21. Zelent A, Greaves M, Enver T: Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 23, 4275-4283 (2004).
22. Kitabayashi I, Yokoyama A, Shimizu K et al.: Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 17, 2994-3004 (1998).
23. Speck NA, Gilliland DG: Core-binding factors in haematopoiesis and leukaemia. Nat. Rev. Cancer 2, 502-513 (2002).
24. Hromas R, Shopnick R, Jumean HG et al.: A novel syndrome of radiation-associated acute myeloid leukemia involving AML1 gene translocations. Blood 95, 4011-4013 (2000).
25. Roulston D, Espinosa R III, Nucifora G et al.: CBFA2(AML1) translocations with novel partner chromosomes in myeloid leukemias: association with prior therapy. Blood 92, 2879-2885 (1998).
26. Sakai I, Tamura T, Narumi H et al.: Novel RUNX1-PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22). Genes, Chromosomes Cancer 44, 265-270 (2005).
27. Stevens-Kroef MJ, Schoenmakers EF, van Kraaij M et al.: Identifcation of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21) (p36;q22)-positive therapy-related AML. Leukemia 20, 1187-1189 (2006).
28. Nucifora G, Begy CR, Kobayashi H et al.: Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21) (q26;q22) translocations. Proc. Natl. Acad. Sci. USA 91, 4004-4008 (1994).
29. Nucifora G, Rowley JD: AML1 and the 8;21 and 3;21 translocation in acute and chronic myeloid leukemia. Blood 86, 1-14 (1995).
30. Nucifora G: The EVI1 gene in myeloid leukemia. Leukemia 11, 2022-2031 (1997).
31. De Braekeleer E, Douet-Guilbert N, Le Bris MJ et al.: 3;21 tran sl ocat ion, trisomy 8 and duplication of the Philadelphia chromosome a rare, but recurrent, cytogenetic pathway in blastic phase of chronic myeloid leukemia. Cancer Genet. Cytogenet. 179, 159-161 (2007).
32. Rubin CM, Larson RA, Anastasi J et al.: t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 76, 2594-2598 (1990).
33. Lo CF, Pisegna S, Diverio D: The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 82, 364-370 (1997).
34. Rowley JD: Identifcaton of a translocation with quinacrine fuorescence in a patient with acute leukemia. Ann. Génét. 16, 109-112 (1973).
35. Gao J, Erickson P, Gardiner K et al.: Isolation of a yeast artifcial chromosome spanning the 8;21 translocation breakpoint t(8;21) (q22;q22.3) in acute myelogenous leukemia. Proc. Natl Acad. Sci. USA 88, 4882-4886 (1991).
36. Miyoshi H, Shimizu K, Kozu T et al.: t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. Proc. Natl Acad. Sci. USA 88, 10431-10434 (1991).
37. Miyoshi H, Kozu T, Shimizu K et al.: The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J. 12, 2715-2721 (1993).
38. Hagemeijer A, Garson OM, Kondo K: Fourth International Workshop on Chromosomes in Leukemia 1982: Translocation (8;21) (q22;q22) in acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 11, 284-287 (1984).
39. Groupe Français de Cytogénétique Hématologique: Acute myelogenous leukemia with an 8;21 translocation. A report on 148 cases from the Groupe Français de Cytogéné tique Hématologique. Cancer Genet. Cytogenet. 44, 169-179 (1990).
40. Romana SP, Poirel H, Le Coniat M et al.: High frequency of t(12;21) in childhood B-lineage acute lymphoblastic leukemia. Blood 86, 4263-4269 (1995).
41. Douet-Guilbert N, Morel F, Le Bris MJ et al.: Fluorescence in situ hybridization study of TEL/AML1 fusion in B-cell acute lymphoblastic leukemia (1984-2002). Cancer Genet. Cytogenet. 144, 143-147 (2003).
42. De Braekeleer E, Basinko A, Douet-Guilbert N et al.: Cytogenetics in pre-B and B-cell acute lymphoblastic leukemia: a study of 208 patients diagnosed between 1981 and 2008. Cancer Genet. Cytogenet. 200, 8-15 (2010).
43. Golub TR, Barker GF, Bohlander SK et al.: Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA 92, 4917-4921 (1995).
44. Romana SP, Mauchauffé M, Le Coniat M et al.: The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85, 3662-3670 (1995).
45. Raimondi SC, Kalwinsky DK, Hayashi Y et al.: Cytogenetics of childhood acute nonlymphocytic leukemia. Cancer Genet. Cytogenet. 40, 13-27 (1989).
46. De Braekeleer E, Douet-Guilbert N, Le Bris MJ et al.: AML1-MTG16 fusion gene in acute myeloblastic leukemia with t(16;21) (q24;q22): case report and review of the literature. Cancer Genet. Cytogenet. 185, 47-50 (2008).
47. Park IJ, Park JE, Kim HJ et al.: Acute myeloid leukemia with t(16;21)(q24;q22) and eosinophilia: case report and review of the literature. Cancer Genet. Cytogenet. 196, 105-108 (2010).
48. Nucifora G, Dickstein JI, Torbenson V et al.: Correlation between cell morphology and expression of the AML1/ETO chimeric transcript in patients with acute myeloid leukemia without the t(8;21). Leukemia 8, 1533-1538 (1994).
49. Gamerdinger U, Teigler-Schlegel A, Pils S et al.: Cryptic chromosomal aberrations leading to an AML1/ETO rearrangement are frequently caused by small insertions. Genes Chromosomes Cancer 36, 261-272 (2003).
50. Mrozek K, Prior TW, Edwards C et al.: Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J. Clin. Oncol. 19, 2482-2492 (2001).
51. Yoo SJ, Chi HS, Jang S et al.: Quantifcation of AML1-ETO fusion transcript as a prognostic indicator in acute myeloid leukemia. Haematologica 90, 1493-1501 (2005).
52. Huang L, Abruzzo LV, Valbuena JR et al.: Acute myeloid leukemia associated with variant t(8;21) detected by conventional cytogenetic and molecular studies: a report of four cases and review of the literature. Am. J. Clin. Pathol. 125, 267-272 (2006).
53. Downing JR, Head DR, Curcio-Brint AM et al.: An AML1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8;21) (q22;q22) translocation. Blood 81, 2860-2865 (1993).
54. De Greef GE, Hagemeijer A, Morgan R et al.: Identical fusion transcript associated with different breakpoints in the AML1 gene in simple and variant t(8;21) acute myeloid leukemia. Leukemia 9, 282-287 (1995).
55. Xue Y, Niu C, Chen S et al.: Two cases of AML (M2) with a t(8;19)(q22;q13): a new cytogenetic variant. Cancer Genet. Cytogenet. 118, 154-158 (2000).
56. Wong KF, Kwong YL, So CC: Translocation(8;20;21)(q22;q13;q22) in acute myeloblastic leukemia with maturation: a variant form of t(8;21). Cancer Genet. Cytogenet. 101, 39-41 (1998).
57. Xue Y, Xu L, Chen S et al.: t(8;21;8) (p23;q22;q22): a new variant form of t(8;21) translocation in acute myeloblastic leukemia with maturation. Leuk. Lymphoma 42, 533-537 (2001).
58. Saitoh K, Miura I, Ohshima A et al.: Translocation (8;12;21)(q22.1;q24. 1;q22.1): a new masked type of t(8;21)(q22;q22) in a patient with acute myeloid leukemia. Cancer Genet. Cytogenet. 96, 111-114 (1997).
59. Harrison CJ, Radford-Weiss I, Ross F et al.: Fluorescence in situ hybridization analysis of masked (8;21)(q22;q22) translocations. Cancer Genet. Cytogenet. 112, 15-20 (1999).
60. Specchia G, Albano F, Anelli L et al.: Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints. Genes Chromosomes Cancer 41, 86-91 (2004).
61. Vasquez-Jimenez EA, Romo-Martinez EJ, Meza-Espinoza JP et al.: A new complex chromosomal translocation t(2;12;21) (q33;p13;q22) in B-cell acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 168, 179-180 (2006).
62. Vieira L, Marques B, Cavaleiro C et al.: Molecular cytogenetic characterization of rearrangements involving 12p in leukemia. Cancer Genet. Cytogenet. 157, 134-139 (2005).
63. Uphoff CC, MacLeod RAF, Denkmann SA et al.: Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines. Leukemia 11, 441-447 (1997).
64. Reddy KS, Yang X, Mak L et al.: A child with ALL and ETV6/AML1 fusion on a chromosome 12 due to an insertion of AML1 and loss of ETV6 from the homolog involved in a t(12;15)(p13;q15). Genes Chromosomes Cancer 29, 106-109 (2000).
65. Nucifora G, Begy CR, Kobayashi H et al.: Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21) (q26;q22) translocations. Proc. Natl. Acad. Sci. USA 91, 4004-4008 (1994).
66. Tighe JE, Calabi F: Alternative, out-of-frame runt/MTG8 transcripts are encoded by the derivative (8) chromosome in the t(8;21) of acute myeloid leukemia M2. Blood 84, 2115-2121 (1994).
67. Gamou T, Kitamura E, Hosoda F et al.: The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8 (ETO) family. Blood 91, 4028-4037 (1998).
68. Mikhail FM, Coignet L, Hatem N et al.: A novel gene, FGA7, is fused to RUNX1/AM L1 in a t(4;21)(q28;q22) in a patient with T-cell acute lymphoblastic leukemia. Genes, Chromosomes Cancer 39, 110-118 (2004).
69. Zhang Y, Emmanuel N, Kamboj G et al.: PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21) (p22;q22). Genes, Chromosomes Cancer 40, 365-370 (2004).
70. Asou N, Yanagida M, Huang L et al.: Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21) (q24;q22) acute myeloid leukemia. Blood 109, 4023-4027 (2007).
71. Paulsson K, Bekassy AN, Olofsson T et al.: A novel and cytogenetically cryptic t(7;21) (p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specifc protease gene USP42. Leukemia 20, 224-229 (2006).
72. Dai HP, Xue YQ, Zhou JW et al.: LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation. Genes Chromosomes Cancer 48, 1027-1036 (2009).
73. Chan EM, Comer EM, Brown FC et al.: AML1-FOG2 fusion protein in myelodysplasia. Blood 105, 4523-4526 (2005).
74. Nguyen TT, Ma LN, Slovak ML et al.: Identifcation of novel Runx1 (AML1) translocation partner genes SH3D19, YTHDf2, and ZNF687 in acute myeloid leukemia. Genes Chromosomes Cancer 45, 918-932 (2006).
75. Chinen Y, Taki T, Nishida K et al.: Identifcation of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene 27, 2249-2256 (2008).
76. Tanaka K, Tanaka T, Kurokawa M et al.: The AML1/ETO (MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2β(CBFβ) in the nucleus more effciently than wild-type AML1. Blood 91, 1688-1699 (1998).
77. Mitani K: Molecular mechanisms of leukemogenesis by AML1/EVI-1. Oncogene 23, 4263-4269 (2004).
78. Sood R, Talwar-Trikha A, Chakrabarti SR et al.: MDS1/EVI1 enhances TGF-β1 signaling and strengthens its growth-inhibitor effect, but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-β1. Leukemia 13, 348-357 (1999).
79. Cuenco GM, Nucifora G, Ren R: Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proc. Natl Acad. Sci. USA 97, 1760-1765 (2000).
80. Nucifora G, Begy CR, Erickson P et al.: The 3;21 translocation in myelodysplasia results in a fusion transcript between the AML1 gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1. Proc. Natl Acad. Sci. USA 90, 7784-7788 (1993).
81. Sacchi N, Nisson PE, Watkins PC et al.: AML1 fusion transcripts in t(3;21) positive leukemia: evidence of molecular heterogeneity and usage of splicing sites frequently involved in the generation of normal AML1 transcripts. Genes Chromosomes Cancer 11, 226-236 (1994).
82. Zhang J, Kalkum M, Yamamura S et al.: E protein silencing by the leukemogenic AML1-ETO fusion protein. Science 305, 1286-1289 (2004).
83. Peterson LF, Zhang DE: The 8;21 translocation in leukemogenesis. Oncogene 23, 4255-4262 (2004).
84. Nevill TJ, Fung HC, Shepherd JD et al.: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92, 1910-1917 (1998).
85. Wang J, Hoshino T, Redner RL et al.: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl Acad. Sci. USA 95, 10860-10865 (1998).
86. Shimada H, Ichikawa H, Nakamura S et al.: Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood 96, 655-663 (2000).
87. Agerstam H, Lilljebjorn H, Lassen C et al.: Fusion gene-mediated truncation of RUNX1 as a potential mechanism underlying disease progression in the 8p11 myeloproliferative syndrome. Genes Chromosomes Cancer 46, 635-643 (2007).
88. Lipsky BP, Beals CR, Staunton DE: Leupaxin is a novel LIM domain protein that forms a complex with PYK2. J. Biol. Chem. 273, 11709-11713 (1998).
89. Chew V, Lam KP: Leupaxin negatively regulates B-cell receptor signaling. J. Biol. Chem. 282, 27181-27191 (2007).
90. Imagama S, Abe A, Suzuki M et al.: LRP16 is fused to RUNX1 in monocytic leukemia cell line with t(11;21)(q13;q22). Eur. J. Haematol. 79, 25-31 (2007).
91. Tsuzuki S, Seto M, Greaves M et al.: Modeling frst-hit functions of the t (12;21) TEL-AML1 translocation in mice. Proc. Natl Acad. Sci. USA 101, 8443-8448 (2004).
92. Bernardin F, Yang Y, Cleaves R et al.: TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. Cancer Res. 62, 3904-3908 (2002).
93. Ramsey H, Zhang DE, Richkind K et al.: Fusion of AML1/Runx1 to Copine VIII, a novel member of the copine family, in an aggressive acute myelogenous leukemia with t(12;21) translocation. Leukemia 17, 1665-1666 (2003).
94. Kitabayashi I, Ida K, Morohoshi F et al.: The AML1-MTG8 leukemic fusion protein forms a complex with a novel member of the MTG(ETO/CDR) family, MTGR1. Mol. Cell. Biol. 18, 846 (1998).
95. Hoogeveen AT, Rossetti S, Stoyanova V et al.: The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t(16;21)-positive myeloid malignancies. Oncogene 21, 6703-6712 (2002).
96. Hromas R, Busse T, Carroll A et al.: Fusion AML1 transcript in a radiation-associated leukemia results in a truncated inhibitory AML1 protein. Blood 97, 2168-2170 (2001).
97. Gelsi-Boyer V, Trouplin V, Adelaide J et al.: Genome profling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes. BMC Cancer 8, 299 (2008).
98. De Braekeleer E, Douet-Guilbert N, Basinko A et al.: Distinct clonal anomalies involving RUNX1 in acute myeloid leukemia at diagnosis and after bone marrow transplantation. Ann. Hematol. 89(12), 1277-1281 (2010).
99. Sakamoto K, Tamamura Y, Katsube K et al.: Zfp64 participates in Notch signaling and regulates differentiation in mesenchymal cells. J. Cell Sci. 121, 1613-1623 (2008).
100. Roche-Lestienne C, Deluche L, Corm S, et al.: RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL + leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111, 3735-3741 (2008).
101. Mitani K, Ogawa S, Tanaka T et al.: Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13, 504-510 (1994).
102. Nucifora G, Birn DJ, Espinosa RI et al.: Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis. Blood 81, 2728-2734 (1993).
103. Mikhail FM, Serry KA, Hatem N et al.: A new translocation that rearranges the AML1 gene in a patient with T-cell acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 135, 96-100 (2002).
104. Salomon-Nguyen F, Busson-Le Coniat M, Lafage-Pochitaloff M et al.: AML1-MTG16 fusion gene in therapy-related acute leukemia with t(16;21)(q24;q22): two new cases. Leukemia 14, 1704-1705 (2000).
105. Nadal N, Stephan JL, Cornillon J et al.: RUNX1 rearrangements in acute myeloblastic leukemia relapsing after hematopoietic stem cell transplantation. Cancer Genet. Cytogenet. 180, 168-169 (2008).
106. Cherry AM, Bangs CD, Jones P et al.: A unique AML1 (CBF2A) rearrangement, t(1;21)(p32;q22), observed in a patient with acute myelomonocytic leukemia. Cancer Genet. Cytogenet. 129, 155-160 (2001).
107. Dai H, Xue Y, Pan J et al.: Two novel translocations disrupt the RUNX1 gene in acute myeloid leukemia. Cancer Genet. Cytogenet. 177, 120-124 (2007).
108. Jeandidier E, Dastugue N, Mugneret F et al.: Abnormalities of the long arm of chromosome 21 in 107 patients with hematopoietic disorders: a collaborative retrospective study of the Groupe Francais de Cytogenetique Hematologique. Cancer Genet. Cytogenet. 166, 1-11 (2006).
109. Richkind K, Hromas R, Lytle C et al.: Identifcation of two new translocations that disrupt the AML1 gene. Cancer Genet. Cytogenet. 122, 141-143 (2000).
110. Slovak ML, Bedell V, Popplewell L et al.: 21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop. Genes Chromosomes Cancer 33, 379-394 (2002).
111. Mikhail FM, Serry KA, Hatem N et al.: A new translocation that rearranges the AML1 gene in a patient with T-cell acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 135, 96-100 (2002).
112. Gogineni SK, Da Costa M, Verma RS: A new translocation, t(5;21)(q13;q22) in acute myelogenous leukemia. Cancer Genet. Cytogenet. 88, 167-169 (1996).
113. Liu S, Li C, Bo L et al.: AML1/RUNX1 fusion gene and t(5;21)(q13;q22) in a case of chronic myelomonocytic leukemia with progressive thrombocytopenia and monocytosis. Cancer Genet. Cytogenet. 152, 172-174 (2004).
114. Mathew S, Head D, Rubnitz JE et al.: Concurrent translocations of MLL and CBFA2 (AML1) genes with new partner breakpoints in a child with secondary myelodysplastic syndrome after treatment of acute lymphoblastic leukemia. Genes Chromosomes Cancer 28, 227-232 (2000).
115. Paulien S, Maarek O, Daniel MT et al.: A novel translocation, t(9;21)(q13;q22) rearranging the RUNX1 gene in acute myelomonocytic leukemia. Ann. Génét. 45, 67-69 (2002).
116. Angelidis P, Kojouri K, Lee J et al.: Trisomy 1q in a patient with severe aplastic anemia. Cancer Genet. Cytogenet. 169, 73-75 (2006).
117. Maseki N, Miyoshi H, Shimizu K et al.: The 8;21 chromosome translocation in acute myeloid leukemia is always detectable by molecular analysis using AML1. Blood 81, 1573-1579 (1993).
118. Shimizu K, Miyoshi H, Kozu T et al.: Consistent disruption of the AML1 gene occurs within a single intron in the t(8;21) chromosomal translocation. Cancer Res. 52, 6945-6948 (1992).
119. Nucifora G, Birn DJ, Erickson P et al.: Detection of DNA rearrangements in the AML1 and ETO loci and of an AML1/ETO fusion mRNA in patients with t(8;21) acute myeloid leukemia. Blood 81, 883-888 (1993).
120. Zhang T, Hillion J, Tong JH et al.: AML-1 gene rearrangement and AML-1-ETO gene expression as molecular markers of acute myeloblastic leukemia with t(8;21). Leukemia 8, 729-734 (1994).
121. Al Bahar S, Adriana Z, Pandita R: A novel variant translocation t(6;8;21)(p22;q22;q22) leading to AML/ETO fusion in acute myeloid leukemia. Gulf. J. Oncology 1, 56-59 (2009).
122. Ahmad F, Kokate P, Chheda P et al.: Molecular cytogenetic fndings in a three-way novel variant of t(1;8;21) (p35;q22;q22): a unique relocation of the AML1/ETO fusion gene 1p35 in AML-M2. Cancer Genet. Cytogenet. 180, 153-157 (2008).
123. Albano F, Specchia G, Anelli L et al.: Submicroscopic deletions in an acute myeloid leukemia case with a four-way t(8;11;16;21). Leuk. Res. 29, 855-858 (2005).
124. Park TS, Song J, Lee KA et al.: Complex t(8;19;21)(q22;p13;q22) as a sole abnormality in a patient with de novo acute myeloid leukemia. Cancer Genet. Cytogenet. 185, 109-112 (2008).
125. Park KJ, Park HD, Kim HJ et al.: A novel four-way t(6;16;21;8)(p21.3;p11. 2;q22;q22) in acute myeloid leukemia with RUNX1/RUNX1T1 rearrangement. Cancer Genet Cytogenet. 192, 90-92 (2009).
126. Satake N, Maseki N, Kozu T et al.: Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br. J. Haematol. 91, 892-898 (1995).
127. Shinagawa A, Komatsu T, Ninomiya H: Complex translocation (6;21;8), a variant of t(8;21), with trisomy 4 in a patient with acute myelogenous leukemia (M2). Cancer Genet. Cytogenet. 109, 72-75 (1999).
128. Sperr WR, Drach J, Hauswirth AW et al.: Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin. Cancer Res. 11, 6787-6792 (2005).
129. Tirado CA, Chen W, Valdez FJ et al.: Acute myeloid leukemia (M2) with a cryptic RUNX1/RUNX1T1 t(1;21;8)(p36;q22;q22) variant. Cancer Genet. Cytogenet. 193, 67-69 (2009).
130. Udayakumar AM, Alkindi S, Pathare AV et al.: Complex t(8;13;21) (q22;q14;q22)-a novel variant of t(8;21) in a patient with acute myeloid leukemia (AML-M2). Arch. Med Res. 39, 25 2-256 (2008).
131. Vieira L, Oliveira V, Ambrosio AP et al.: Translocation (8;17;15;21) (q22;q23;q15;q22) in acute myeloid leukemia (M2). a four-way variant of t(8;21). Cancer Genet. Cytogenet. 128, 104-107 (2001).
132. Vundinti BR, Kerketta L, Madkaikar M et al.: Three-way translocation in a new variant of t(8;21) acute myeloid leukemia involving Xp22. Indian J. Cancer 45, 30-32 (2008).
133. Zhang J, Liu Z, Shao H et al.: Laboratory study of a complex translocation t(2;8;21) (p12;q22;q22) in a patient with acute myelogenous leukemia. Leuk. Lymphoma 49, 1925-1928 (2008).
134. Farra C, Awwad J, Valent A et al.: Complex translocation (8;12;21): a new variant of t(8;21) in acute myeloid leukemia. Cancer Genet. Cytogenet. 155, 138-142 (2004).
135. van Lom K, Hagemeijer A, Vandekerckhove F et al.: Clonality analysis of hematopoietic cell lineages in acute myeloid leukemia and translocation (8;21): only myeloid cells are part of the malignant clone. Leukemia 11, 202-205 (1997).
136. Gallego M, Carroll AJ, Gad GS et al.: Variant t(8;21) rearrangements in acute myeloblastic leukemia of childhood. Cancer Genet. Cytogenet. 75, 139-144 (1994).
137. Hagemeijer A, de Klein A, Wijsman J et al.: Development of an interphase fuorescent in situ hybridization (FISH) test to detect t(8;21) in AML patients. Leukemia 12, 96-101 (1998).
138. Hsiao HH, Sashida G, Kodama A et al.: Variant translocation t(2;21;8)(q36;q22;q22) with RUNX1/CBFA2T1 (AML1/ETO) transcript in a case of acute myelogenous leukemia. Cancer Genet. Cytogenet. 159, 96-97 (2005).
139. Ishida F, Ueno M, Tanaka H et al.: t(8;21;14)(q22;q22;q24) is a novel variant of t(8;21) with chimeric transcripts of AML1-ETO in acute myelogenous leukemia. Cancer Genet. Cytogenet. 132, 133-135 (2002).
140. Kelly MJ, Meloni-Ehrig AM, Manley PE et al.: Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6. Cancer Genet. Cytogenet. 189, 48-52 (2009).
141. Kikuchi A, Hanada R, Yamamoto K: Novel three-way translocation t(5;8;21) in acute myeloblastic leukemia (M2) with chloroma. J. Pediatr. Hematol. Oncol. 21, 452-454 (1999).
142. Starza RL, Matteucci C, Crescenzi B et al.: Identifcation of chromosome changes in acute myeloid leukemia (AML-M2) by molecular cytogenetics. Cancer Genet. Cytogenet. 95, 148-152 (1997).
143. Lau LC, Koh LP, Lim TH et al.: A cryptic three-way translocation involving chromosomes 8, 14, and 21 in a case of acute myeloid leukemia subtype M1. Cancer Genet. Cytogenet. 163, 86-90 (2005).
144. Lee J, Kern WF, Cain JB et al.: A variant t(8;10;21) in a patient with pathological features mimicking atypical chronic myeloid leukemia. Cancer Genet. Cytogenet. 159, 79-83 (2005).
145. Mathew S, Shurtleff S, Ribeiro RC et al.: A complex variant t(8;21) involving chromosome 3 in a child with acute myeloblastic leukemia with eosinophilia (AML M4Eo). Leuk. Lymphoma 44, 183-187 (2003).
146. Mitterbauer M, Kusec R, Schwarzinger I et al.: Comparison of karyotype analysis and RT-PCR for AML1/ETO in 204 unselected patients with AML. Ann. Hematol. 76, 139-143 (1998).
147. Taviaux S, Brunel V, Dupont M et al.: Simple variant t(8;21) acute myeloid leukemias harbor insertions of the AML1 or ETO genes. Genes Chromosomes Cancer 24, 165-171 (1999).